



Media Releases » Torrent Pharma announces Q3 FY 14-15 results
January 28th, 2015

| Financial Highlights of Q3 FY 14-15 vs YTD FY 14-15 | | | | | | |
|---|----------|----------|--------|-----------|-----------|--------|
| Financial Metric | Q3 FY 14 | | Growth | YTD FY 14 | | Growth |
| | Q3 FY 14 | Q3 FY 14 | | YTD FY 14 | YTD FY 14 | |
| Revenue | 1,108 | 1,211 | 8% | 1,099 | 1,279 | 8% |
| EBITDA | 257 | 322 | 26% | 1,041 | 1,421 | 36% |
| % Annual | 20% | 22% | | 20% | 22% | |
| Patentable molecule | 31 | 33 | 7% | 31 | 32 | 0% |
| % Annual | 1% | 1% | | 1% | 1% | |
| Patent | 37 | 39 | 6% | 41 | 43 | 6% |
| % Annual | 2% | 2% | | 2% | 2% | |

- For Q314-15 revenues were at Rs. 1,168 crores, up by 15% from Rs. 1,015 crores during the same period last year.
- EBITDA for Q314-15 was at Rs. 305 crores up by 36% from Rs. 225 crores during the same period last year.
- PAT for Q314-15 was at Rs. 167 crores up by 6% compared to Rs. 158 crores during the same period last year.
- Company declared an interim dividend of 100% (Rs. 5/- per share).

Performance Highlights of Q3 FY 15

- Domestic formulation business recorded revenues of Rs. 420 crores, growing by 42%.
 - Current quarter includes sales from acquired Elder business. Excluding this sales growth for quarter would have been 15%.
 - As per AIOCD; acquired Elder business growth was 15% compared to covered market de growth of 5% on rolling quarter basis.
- International revenues grew by 4% to Rs. 660 crores. Adjusting for currency movements revenues grew by 11%.
 - Revenues from US operations recorded growth of 16%.
 - Operations in Brazil registered revenue growth of 6%. Adjusting for currency movements revenues grew by 19%.
 - Revenues from Europe (incl. Germany) recorded a de growth of -9%.
 - Revenues from Rest of the World including Russia & Mexico operations recorded revenue growth of 12%.

Performance Highlights of YTD Dec 14

- Domestic formulation business recorded revenues of Rs. 1,216 crores, growing by 34%.
 - Current period includes sales from acquired Elder business. Excluding this sales growth for the period would have been 15%.
- International revenues grew by 18% to Rs. 2,065 crores. Adjusting for currency movements revenues grew by 19%.
 - Revenues from US operations recorded growth of 62%.
 - Operations in Brazil registered revenue growth of 15%. Adjusting for currency movements revenues grew by 21%.
 - Revenues from Europe (incl. Germany) recorded a growth of 4%.
 - Revenues from Rest of the World including Russia & Mexico operations were flat.

About Torrent Pharma

Torrent Pharma, with an annual turnover of almost Rs. 4200 crores is the flagship Company of the Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry. Torrent has a full equipped Research Center, employing almost 600 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Intrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.